Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Spero Therapeutics, Inc. (Nasdaq: SPRO) announced on November 30, 2020, the grant of non-qualified stock options for 76,200 shares to ten new employees under its 2019 Inducement Equity Incentive Plan. The options, with an exercise price of $16.57 per share, incentivize new hires aligned with Nasdaq Listing Rule 5635(c)(4). Each option will vest over four years, with 25% vesting after the first year and the remainder monthly. Spero focuses on treatments for multi-drug resistant infections and rare diseases, such as its lead candidate, tebipenem HBr, which showed positive results in a Phase 3 trial.

Positive

• Grant of 76,200 stock options to new employees, supporting recruitment efforts.
• The options have an exercise price aligned with the market, potentially incentivizing performance.
• Positive results from the Phase 3 clinical trial of tebipenem HBr, enhancing product pipeline credibility.

Negative

• None.

CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on November 30, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 76,200 shares of its common stock to ten new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spero (or following a bona fide period of non-employment), as an inducement material to such individuals’ entering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The options have an exercise price of $16.57 per share, which is equal to the closing price of Spero’s common stock on The Nasdaq Global Select Market on November 30, 2020. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36-months, subject to each employee’s continued employment with Spero on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

About Spero Therapeutics
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections and rare diseases.

Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.

Spero is also advancing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.

Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting.

For more information, visit https://sperotherapeutics.com.

Spero Investor and Media Contact:
Sharon Klahre
Vice President, Investor Relations
857-242-1547
IR@sperotherapeutics.com

FAQ

What recent stock options were granted by Spero Therapeutics (SPRO)?

Spero Therapeutics granted non-qualified stock options to purchase 76,200 shares to ten new employees on November 30, 2020.

What is the exercise price of the stock options granted by Spero Therapeutics (SPRO)?

The exercise price of the stock options is $16.57 per share.

What is the vesting schedule for the stock options granted by Spero Therapeutics (SPRO)?

The options will vest over four years, with 25% vesting after the first year and the remaining shares vesting monthly over the following three years.

What is the primary focus of Spero Therapeutics (SPRO)?

Spero Therapeutics focuses on developing treatments for multi-drug resistant bacterial infections and rare diseases.

What are the implications of the stock options grant for Spero Therapeutics (SPRO)?

The stock options grant serves as an inducement for new talent, potentially improving operational capabilities and driving future growth.